Xaar Share Discussion Threads

[john09] 01/10/2021 08:59

Yes case in point - I wouldn’t have touched Heiq and they’ve barely mentioned it since

[iandippie] 01/10/2021 08:57

I think the answer to that is basically stick to the ones scsw is confident enough to put in its own portfolio. They live or die by that, and you can't argue with 500% growth in 6 years.

[dangersimpson2] 01/10/2021 08:51

140p looks like fairly strong support on the chart, and then around 120p if that fails.

[john09] 01/10/2021 08:50

I must confess on XAAR ive read the articles and then i ended u on XAARs website and started watching videos of interviews of Chinese people and not sure i understand what the opportunity is. That’s what’s discouraged me from this one. I dont get it but i know its well backed !

[dr biotech] 01/10/2021 08:46

I’ve taken the hit here. Scsw has given me some decent risers but this has dropped 40% in a few weeks add that to Heiq (-50%) and several others that have performed woefully over the last couple of months (bango/superdry) and I’m wondering whether to keep the faith.

Not a big position here for me, but overall the last few weeks have been the worst since the beginning of the pandemic.

[sickofit] 30/9/2021 13:49

Based on what? Random thoughts?

[northwards] 30/9/2021 10:43

Suspect China supply chain issues are weighing here.

[volsung] 28/9/2021 07:30

Bought a few more at 180.53p
Crucial point chartwise
Hopefully a bounce from here

[ny boy] 24/9/2021 11:33

General equity markets could easily sell off sharply, too much complacency around, wait until the China dominos start to fall when Evergrande defaults, rock period ahead imo, not buying these yet, will see if the market allows me to buy 140-150p area over the coming month

[zho] 16/9/2021 06:24

Simon Thomson in Investors' Chronicle:

The price has since pulled back close to my last entry point (185p) on profit taking which means that Xaar is now rated on an enterprise valuation to cash profit multiple of 9 for 2023, hardly excessive for a recovery stock. I am tweaking my target up slightly from 220p to 230p and continue to rate the shares a buy.



(Search on text to access whole article)

[northwards] 15/9/2021 08:41

Investec raises its target to 280p. https://twitter.com/SCSWSharewatch/status/1437766835718574080?s=20

[dr biotech] 14/9/2021 16:40

Seems the uncertain outlook is to blame. Similar article in sharecast to the one below.




hxxps://www.sharesmagazine.co.uk/news/shares/xaar-sinks-12-on-wider-first-half-loss



Inkjet printing technology specialist Xaar (XAR) fell 12.3% to 190p after posting a deeper first half loss as rising revenue was offset by increased expenses, including higher R&D spending.

This, plus a highly caveated outlook statement, appeared to prompt fears of an eventual profit warning, despite the company sticking with full year guidance for now.

Often a weak first half creates a situation where a company struggles to catch up and is eventually forced to guide full-year expectations lower.

Pre-tax losses for the six months through June amounted to £5.6 million, compared to £4.8 million for the same six month period a year earlier.

Revenue rose 11% to £26.3 million, which Xaar said was in line with its expectations.

3D PRINTING SALE TAKES LONGER THAN EXPECTED

The company said it would announce details of a planned sale of its 3D-printing division soon, while admitting the process had taken longer than expected.

Notwithstanding the proceeds from any sale of this business the company was sitting on net cash of £17.1 million.

‘We are pleased with our continued strong performance which, despite challenging market conditions, demonstrates the success of our strategy and underlying strength of the business,’ chief executive John Mills said.

‘Our foundations remain strong, as we continue to gain new customers and positively re-engage in our core markets.’

‘The Covid-19 pandemic continues to cause disruption for business, however we are determined to minimise interruption to the supply of printheads, and we are well-positioned to withstand further volatility caused by the pandemic.’

[malcolmmm] 14/9/2021 15:21

Its MRCH they are up today I think

[farmergeorge] 14/9/2021 15:17

Malcolmmm, thanks. What's the epic for the Merchants board?

[malcolmmm] 14/9/2021 14:59

Yes just bought a few more, see how they finish today

[investoree] 14/9/2021 14:57

The more of these I buy the lower the price goes, hopefully no bad news in the pipeline.

[malcolmmm] 14/9/2021 13:48

farmergeorge take a look on the MERCHANTS board . Its been known for some time that we are cheap .A lot of funds think we are cheap
A Latter says despite excellent gains made by fund managers since the market lows, UK equities continue to operate at a 40 per cent discount to their peers - a 30 year-low, so there is still a lot of catching up to do.

[zho] 14/9/2021 13:24

Thank montynj,

That's a tweet from SCSW, in case anyone wondered.

[montynj] 14/9/2021 13:20

Investec note out on #XAR "Revenue was ahead, on strong Ceramics & Glass volumes. The sale of Xaar 3D expected in 4Q21. Investec'sTP up by 30% to 280p, highlighting the profit trajectory and self-help."

[farmergeorge] 14/9/2021 13:13

Malcommm, ok noted. Fingers crossed it doesn't spike down even more or you could get caught. Who's 'they'? Thanks.

[malcolmmm] 14/9/2021 12:55

farmergeorge no stoploss at present as they could swing about for awhile , I have been caught out with a 12% downward split second spike before.Wait to they stabilise imo.
But never know with the stock market. But they recon UK shares are cheap

[dr biotech] 14/9/2021 11:56

This looks like the sort of publication that you'd hide inside the cover of a porno mag to stop embarassing yourself. Still its good that they are getting it out there today. I've added a small amount here on the dip. Sold out of Staffline thats also had a wobble on results. Hope thats the right decision.


hxxps://www.labelsandlabeling.com/news/new-products/xaar-introduces-irix-printhead